Millions of people across the world benefit from weight loss drugs such as Ozempic based on the hormone GLP-1. In the new ...
"While GLP-1-based therapies have revolutionized patient care for obesity ... In 2023, Embark Biotech was acquired by Novo Nordisk to develop next generation therapeutics for cardiometabolic disease.